Navigation Links
Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2013

ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  Mr. Riley is scheduled to present at 12:05 p.m. (Eastern Time) on Monday, September 9, 2013 at the Millennium Broadway Hotel in New York City.

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://wsw.com/webcast/rrshq23/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
2. Synthetic Biologics to Report Second Quarter 2013 Financial Results
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. New England Biolabs supports iGEM synthetic biology competition
7. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
8. Intrexon Organizes Around New Synthetic Biology Markets
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
11. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):